EGFR and non-small cell lung carcinoma: However, due to the acquired resistance by the mutations such as EGFR<sup>T790M</sup> and EGFR<sup>C797S</sup> together with the exon 20 insertion mutations, these drugs do not provide promising results for NSCLC patients.